BDX - Becton, Dickinson and Company

NYSE - NYSE Delayed Price. Currency in USD

Becton, Dickinson and Company

1 Becton Drive
Franklin Lakes, NJ 07417
United States
201-847-6800
http://www.bd.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees65,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Vincent A. ForlenzaExec. Chairman3.26M15.95M1953
Mr. Thomas E. Polen Jr.Pres, CEO & Director1.93M2.79M1973
Mr. Christopher R. ReidyExec. VP, CFO & Chief Admin. Officer1.74MN/A1957
Mr. Alberto MasExec. VP & Pres of the Medical Segment1.32M1.22M1961
Mr. Patrick K. KaltenbachExec. VP & Pres of the Life Sciences Segment2.03M107.67k1963
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Corporate Governance

Becton, Dickinson and Company’s ISS Governance QualityScore as of February 3, 2020 is 9. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.